New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 10mg;  ;   - film coated tablet - 10 mg - active: empagliflozin 10mg     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 25mg;  ;   - film coated tablet - 25 mg - active: empagliflozin 25mg     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation; tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation - solution for inhalation - 2.5mcg/2.5mcg - active: olodaterol hydrochloride 0.0248%{relative} equivalent to to olodaterol 2.5mcg per actuation tiotropium bromide monohydrate 0.0283%{relative} equivalent to to tiotropium 2.5mcg per actuation excipient: benzalkonium chloride disodium edetate hydrochloric acid purified water - spiolto respimat is indicated for the long term, once daily maintenance treatment in patients with copd (including chronic bronchitis and emphysema), to reduce airflow obstruction, to improve quality of life, and to reduce associated dyspnoea.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 100 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - nintedanib as esilate - capsules soft - nintedanib as esilate 150 mg - idiopathic pulmonary fibrosis ofev is indicated for the treatment of idiopathic pulmonary fibrosis (ipf) in adults. systemic sclerosis-associated interstitial lung diseaseofev is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (ssc-ild).chronic fibrosing interstitial lung diseases with a progressive phenotypeofev is indicated in adults for the treatment of chronic fibrosing interstitial lung diseases (ilds) with a progressive phenotype

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 10 mg - linagliptin and empagliflozin - jardiance 10mg is indicated: •to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure.•as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus •to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - film coated tablets - empagliflozin 25 mg - linagliptin and empagliflozin - jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 10 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin; linagliptin - film coated tablets - linagliptin 5 mg; empagliflozin 25 mg - linagliptin and empagliflozin - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate. limitations of useglyxambi is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.glyxambi has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using glyxambi.

Israel - English - Ministry of Health

boehringer ingelheim israel ltd. - olodaterol as hydrochloride; tiotropium bromide as monohydrate - solution for inhalation - olodaterol as hydrochloride 2.5 mcg; tiotropium bromide as monohydrate 2.5 mcg - vilanterol and umeclidinium bromide - spiolto respimat is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).